UNSPSC 51101670: Moxidectin

This classification denotes an antiparasitic agent with the molecular formula C37H53NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NGU5H31YO9, chemically known as milbemycin b, 5-o-demethyl-28-deoxy-25-((1e)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6r,23e,25s)- but generally known as moxidectin, which bears US NIH Compound Identifier 9571036. European Medicines Agency schedules Moxidectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09085MIG.

UNSPSC 51101670 Moxidectin, a Commodity code, nominally identifies veterinary parasiticides, but recent state and local procurement activity shows no solicitations for moxidectin itself. Instead, the code tags pharmaceutical and medical supply procurements—naloxone, generic multi-source pharmaceuticals, OTC products, and emergency medical consumables—that fall outside the code's intended scope. State and local issuing bodies under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal purchasing departments (City of Tampa), and cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance). The work being solicited is supply and distribution of drugs and medical products through existing wholesaler networks, direct-to-manufacturer contracting arrangements, and traditional sealed-bid purchasing.

Geographic activity clusters in Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to the county community health building); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00 with a certified Small Local Business Enterprise set-aside and 5 percent bid discount (due March 13, 2026); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (proposals due March 26, 2026, with awards effective July 1, 2026); and the Texas HHS Commission's RFI soliciting vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program (response deadline April 3, 2026). The code shows material recent activity in pharmaceutical and medical supply procurement, though moxidectin-specific solicitations are absent from the recent record.